Composition of the different artificial soils and treatment of the experiment.

<p>Composition of the different artificial soils and treatment of the experiment.</p

Relative bioavailability (RBA) factors of NDL-PCBs.

<p>RBA factors were calculated from adjusted means of concentrations (ng.g⁻¹ of fat). Values in brackets indicates 95% confidence interval (2xSE). SE were calculated via propagation of errors formula.</p><p>Multivariate analysis was performed using GLM procedure on RBA values 95% confidence interval (2xSE) was calculated.</p><p>Organic matter effect: letters (a, b, c, d, e, f) indicate values that do not statistically differ from other values within column presenting a common letter (P<0.05).</p><p>NDL-PCBs effect: letters (A, B) indicate values that do not statistically differ from other values within line presenting a common letter (P<0.05).</p><p>RMSE: Root means square error.</p><p>Relative bioavailability (RBA) factors of NDL-PCBs.</p

Mechanistic approach of retention and bioavailability of NDL-PCBs bound to OM.

<p>Mechanistic approach of retention and bioavailability of NDL-PCBs bound to OM.</p

Concentrations (ng.g⁻¹ of fat) of NDL-PCBs in adipose tissue.

<p>Each value represents the adjusted mean ± standard error. Values are presented following treatment groups: Spiked corn oil (SO, n  = 5); Standard soil without organic matter (SS, n  = 4); 1% OC Fulvic acid soil (FA, n  = 4); 1% OC <i>Sphagnum</i> peat soil (SP, n  = 5); 1% OC <i>Sphagnum</i> peat soil; Activated Carbon (95∶5) (SPAC, n  = 5); 1% OC Humic acid soil (HA, n  = 5); 1% Activated carbon (AC, n  = 5); Negative controls (NC, n  = 5). Letters (a, b, c, d, e, f) indicate values that do not statistically differ from other values within groups presenting a common letter (<i>P</i><0.05).</p

Animal management and experimental design of the study.

<p>Animal management and experimental design of the study.</p

Concentrations of CLD in biological matrices (ng of CLD per g of DM).

<p>Concentrations of CLD are expressed in ng.g^-1 of DM. Values correspond to the mean ± SD. Mean values with different superscript letters (a, b, c) were statistically different (P<0.05). Statistical analysis was performed using the two-way ANOVA procedure of R software and a Tukey post-hoc test. Two effects were used in the model: Organ and Treatment. Both effects were significant (p<0.0001) and RMSE = 12.84. (n = 5). RMSE: Root means square error. #: values are below limit of quantification (LOQ).</p

Relative bioavailability factors of CLD in biological matrices (% and 95% confidence interval).

<p>Relative bioavailability factors of CLD in biological matrices (% and 95% confidence interval).</p

Reduction factor (%, based on 95th confidence interval).

<p>Reduction factor (%, based on 95th confidence interval).</p

Hazard ratios and 95% confidence intervals for risk of breast cancer in relation to number of nevi, stratified by hormonal receptor status, E3N cohort (<i>n = </i>88,387).

<p>Women with missing information on hormone receptor status were excluded from this analysis (<i>n = </i>1,415).</p>b<p>Adjusted for age (timescale), education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), and use of premenopausal progestogens, and stratified according to year of birth in 5-y categories (Model 2).</p>c<p>Additionally adjusted for personal history of BBD and family history of breast cancer (model used for homogeneity test) (Model 4).</p

Hazard ratios and 95% confidence intervals for risk of breast cancer in relation to number of nevi, E3N cohort (<i>n = </i>89,802).

a<p>Adjusted for age (timescale), education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), and use of premenopausal progestogens, and stratified according to year of birth in 5-y categories.</p>b<p>Model 2 additionally adjusted for personal history of BBD.</p>c<p>Model 3 additionally adjusted for personal history of BBD and family history of breast cancer.</p>d<p>Model 4 additionally adjusted for BMI, height, physical activity, age at menarche, age at first full-term pregnancy, parity, breastfeeding, use of OCs, history of mammographic exam, UV dose in county of birth, and UV dose in county of residence at inclusion.</p